{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-317541","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2025-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.123062+00:00","generated_at":"2026-05-16T13:21:51.333821+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"GSK terminates collaboration on IDE275 and IDE705; programs returning to IDEAYA","bullets":["GSK gave written notice on Dec 9, 2025 to terminate the June 2020 Collaboration, Option and License Agreement.","Termination effective March 9, 2026; 90-day transition for GSK to transfer Werner Helicase (IDE275) and Pol Theta (IDE705) programs.","IDEAYA will evaluate strategic options for IDE275 and IDE705 in 2026.","Cash runway guidance into 2030 remains unchanged despite the termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-317541","json":"https://secwatch.observer/filing/0001193125-25-317541.json","markdown":"https://secwatch.observer/filing/0001193125-25-317541.md","text":"https://secwatch.observer/filing/0001193125-25-317541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312525317541/0001193125-25-317541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312525317541/d800445d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:21:51.333821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}